As previously reported, Stifel analyst Alex Thompson downgraded Pliant Therapeutics (PLRX) to Hold from Buy with a price target of $3, down

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week low of $1.53 earlier in the session, and is now down 90% n the past 12 months.

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli